ATE232743T1 - Bor enthaltende hormonanaloga und verfahren fuer ihre verwendung zur bildlichen darstellung oder zum abtoeten von zellen, die hormonrezeptoren besitzen - Google Patents

Bor enthaltende hormonanaloga und verfahren fuer ihre verwendung zur bildlichen darstellung oder zum abtoeten von zellen, die hormonrezeptoren besitzen

Info

Publication number
ATE232743T1
ATE232743T1 AT95921291T AT95921291T ATE232743T1 AT E232743 T1 ATE232743 T1 AT E232743T1 AT 95921291 T AT95921291 T AT 95921291T AT 95921291 T AT95921291 T AT 95921291T AT E232743 T1 ATE232743 T1 AT E232743T1
Authority
AT
Austria
Prior art keywords
cells
boron
hormone receptor
containing moiety
hormone
Prior art date
Application number
AT95921291T
Other languages
English (en)
Inventor
M Frederick Hawthorne
Mark T Groudine
Original Assignee
Neutron Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutron Therapies Inc filed Critical Neutron Therapies Inc
Application granted granted Critical
Publication of ATE232743T1 publication Critical patent/ATE232743T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
AT95921291T 1994-06-27 1995-05-15 Bor enthaltende hormonanaloga und verfahren fuer ihre verwendung zur bildlichen darstellung oder zum abtoeten von zellen, die hormonrezeptoren besitzen ATE232743T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26628294A 1994-06-27 1994-06-27
PCT/US1995/006284 WO1996000090A1 (en) 1994-06-27 1995-05-15 Boron-containing hormone analogs and methods of their use in imaging or killing cells having hormone receptors

Publications (1)

Publication Number Publication Date
ATE232743T1 true ATE232743T1 (de) 2003-03-15

Family

ID=23013931

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95921291T ATE232743T1 (de) 1994-06-27 1995-05-15 Bor enthaltende hormonanaloga und verfahren fuer ihre verwendung zur bildlichen darstellung oder zum abtoeten von zellen, die hormonrezeptoren besitzen

Country Status (8)

Country Link
US (1) US6074625A (de)
EP (1) EP0729363B1 (de)
JP (1) JPH11505504A (de)
AT (1) ATE232743T1 (de)
AU (1) AU696788B2 (de)
CA (1) CA2170400A1 (de)
DE (1) DE69529665T2 (de)
WO (1) WO1996000090A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US6083936A (en) * 1999-01-25 2000-07-04 Sri International Boron heterocycle steroid mimics and associated pharmaceutical compositions and methods of use
US6806363B1 (en) * 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
US7591995B2 (en) * 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
MXPA02003772A (es) 1999-10-15 2005-04-28 Mayo Foundation Conjugados de cobalamina, utiles como agentes para obtencion de imagen y como agentes terapeuticos.
JP2003512338A (ja) * 1999-10-15 2003-04-02 メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ 造影剤および抗腫瘍薬として有用なコバラミン結合体
US7122172B1 (en) 2000-03-08 2006-10-17 Gerhart Graupner Methods and compositions for targeted drug delivery
US7906103B2 (en) * 2000-03-08 2011-03-15 Gerhard Graupner Methods and compositions for targeted drug delivery
WO2002055530A2 (en) * 2000-10-25 2002-07-18 Mayo Foundation Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
EP1435973A4 (de) * 2001-09-28 2007-05-02 Mayo Foundation Gleichzeitige verabreichung eines transportproteins mit konjugiertem cobalamin zur abgabe von mitteln
CA2478093A1 (en) * 2002-02-28 2003-09-12 A & D Bioscience, Inc. Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
US20050107310A1 (en) * 2002-03-19 2005-05-19 Holick Michael F. Carboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
US20050233949A1 (en) * 2002-04-12 2005-10-20 Holick Michael F Conjugates comprising cancer cell specific ligands, a sugar and cancer chemotherapeutic agents/boron neutron capture therapy agents, and uses thereof
EP1549323A2 (de) * 2002-05-07 2005-07-06 A & D Bioscience, Inc. Konjugate mit einem wirkstoff für das zentrale nervensystem
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
US8535750B2 (en) * 2005-05-17 2013-09-17 Cargill, Incorporated Granular lecithins, granular lysolecithins, process for their production and compositions containing them
US20080050309A1 (en) * 2006-08-25 2008-02-28 Hadron Systems Compositions of pharmaceuticals for use in low energy neutron therapy
JP5248003B2 (ja) * 2006-09-25 2013-07-31 浩之 中村 ホウ素イオンクラスター型コレステロール及びリポソーム
US7572458B2 (en) 2007-06-11 2009-08-11 Ewha University-Industry Collaboration Foundation Boron compound-layered double hydroxide nanohybrid, method of preparing the boron compound-LDH nanohybrid, and pharmaceutical composition comprising the boron compound-LDH nanohybrid
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
AU2020274113A1 (en) 2019-05-14 2021-11-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2021097046A1 (en) 2019-11-13 2021-05-20 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
AU2022246058A1 (en) 2021-03-23 2023-10-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
AU2022269568A1 (en) 2021-05-03 2023-11-16 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2023069711A1 (en) * 2021-10-22 2023-04-27 Trustees Of Tufts College Fap-targeted neutron capture agents, and uses and formulations related thereto

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995060A (en) * 1972-06-20 1976-11-30 Schering Corporation Antiandrogenic agents and method for the treatment of androgen dependent disease states
US4329364A (en) * 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
GB1560274A (en) * 1977-02-28 1980-02-06 Ici Ltd Phenylbut 1-ene derivatives having antiostrogenicactivity
EP0002097B1 (de) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalken-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
US4206234A (en) * 1977-08-22 1980-06-03 Imperial Chemical Industries Limited Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof
US4191775A (en) * 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
ATE1418T1 (de) * 1979-05-15 1982-08-15 Imperial Chemical Industries Plc 1-hydrocarbyloxyphenyl-1.2-diphenylalkenderivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzung.
NZ197008A (en) * 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
DE3372965D1 (en) * 1982-07-23 1987-09-17 Ici Plc Amide derivatives
US4466952A (en) * 1983-01-12 1984-08-21 Indiana University Foundation Compositions and process for the treatment of cancer
GB8311678D0 (en) * 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
CA1229604A (en) * 1984-02-14 1987-11-24 Lorne J. Brandes Aminoalkyl ethers of phenols as antiproliferative anticancer agents
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
GB2196003A (en) * 1986-09-11 1988-04-20 Nat Res Dev Iodo-and bromo-tamoxifen derivatives
US4921941A (en) * 1987-07-01 1990-05-01 Schering Corporation Orally active antiandrogens
US5066479A (en) * 1988-05-31 1991-11-19 The Regents Of The Univ. Of California Metallacarborane chelates
CA2034042C (en) * 1990-01-18 1999-08-17 Adrian D. Nunn Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group
US5219548A (en) * 1990-10-01 1993-06-15 Board Of Regents, The University Of Texas System High affinity halogenated-tamoxifen derivatives and uses thereof
US5443813A (en) * 1991-06-06 1995-08-22 Associated Universities, Inc. Loading and conjugating cavity biostructures
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
US5286853A (en) * 1992-09-11 1994-02-15 Boron Biologicals, Inc. Boron-gadolinium compounds and method of conducting imaging and/or neutron capture therapy with same
US5599796A (en) * 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
WO1995026359A1 (en) * 1994-03-25 1995-10-05 Regents Of The University Of California Macromolecular structures for boron neutron-capture therapy
US5630786A (en) * 1994-06-27 1997-05-20 Ionix Corporation Boron neutron capture enhancement of fast neutron therapy

Also Published As

Publication number Publication date
EP0729363B1 (de) 2003-02-19
AU2640795A (en) 1996-01-19
US6074625A (en) 2000-06-13
WO1996000090A1 (en) 1996-01-04
DE69529665T2 (de) 2004-02-19
DE69529665D1 (de) 2003-03-27
EP0729363A1 (de) 1996-09-04
CA2170400A1 (en) 1996-01-04
AU696788B2 (en) 1998-09-17
EP0729363A4 (de) 1998-08-19
JPH11505504A (ja) 1999-05-21

Similar Documents

Publication Publication Date Title
ATE232743T1 (de) Bor enthaltende hormonanaloga und verfahren fuer ihre verwendung zur bildlichen darstellung oder zum abtoeten von zellen, die hormonrezeptoren besitzen
WO2006044174A3 (en) Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor
PT981369E (pt) Composicoes imunogenicas para o receptor de cck-b/gastrina e metodos para o tratamento de tumores
JP2002524126A5 (de)
NO984136D0 (no) Humanisert kimært antistoffmolekyl for bruk som dianostikum, og diagnostisk preparat omfattende et slikt antistoffmolekyl
PE20110001A1 (es) Derivados de taxanos como agentes citotoxicos
ATE177535T1 (de) Identifizierung von liganden durch selektive vermehrung von, durch rezeptoren tranzfizierten zellen
NO931153L (no) Vannloeselige camptothecin-analoger fremgangsmaater og metoder
DE3750630D1 (de) Verwendung von einem Antikörperkonjugat zum Nachweis von nekrotischem malignem Gewebe und für die assoziierte Therapie.
DK96588D0 (da) Antitumirmiddel indeholdende makromolekylaere platinforbindelser
DE69125286D1 (de) Vorrichtung zum neutralisieren elektrisch geladenen materials
Miledi Induced innervation of end-plate free muscle segments
DE68918144T2 (de) System zur Belichtung mittels geladener Teilchenstrahlen.
SE8003732L (sv) Sett vid bestemningsmetoder involverande biospecifika affinitetsreaktioner
PT97423A (pt) Processo para a preparacao de composicoes farmaceuticas contendo conjugados de anticorpos para o tratamento de neoplasias
NL193560B (nl) Werkwijze en inrichting voor het bevestigen van een anode aan een onder water opgestelde constructie.
ES2106890T3 (es) Antigeno linfoide cd30.
van Koppen et al. Autoradiographic visualization of muscarinic receptors in pulmonary nerves and ganglia
DE69001171T2 (de) Vorrichtung zur Enthärtung von Wasser mittels Entkarbonisierung.
Gazyakan et al. Postnatal development of opioid receptors modulating acetylcholine release in hippocampus and septum of the rat
LU80171A1 (fr) Procede de solubilisation de l'erythrosine dans des conditions acides,et compositions obtenues
ATE311101T1 (de) Abbildung von transgenen markern
FR2840446B1 (fr) Procede de retraitement d'un combustible nucleaire epuise
JPS5381393A (en) Method for producing earthworms for feeding and medical use and earthworm excremental soil for fertilizer by utilizing droppings of swine* chicken0and cattle etc* and wastes from processes for process
SU1766257A3 (ru) Способ получени производных стильбена

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties